Suppressing Repurposed Drugs ‘Cost Millions of Lives’: Founder of COVID Treatment Fund
The executive director of the Vaccine Safety Research Foundation, Steve Kirsch, has been working to make early COVID drug treatments available to the public, despite being assailed by the medical establishment for speaking out about the dangers of the COVID vaccines.
During the pandemic, he founded the COVID-19 Treatment Fund to raise money to test repurposed drugs for use in treating COVID, while health agencies were dismissing their effectiveness and urging the public to get vaccinated as the only way to prevent severe illness and hospitalization.
Not allowing the testing and use of repurposed drugs has cost too many lives said, Kirsch.
“This has cost millions of lives,” and the problem was compounded by a hospital COVID treatment protocol “that was almost certain to kill you,” Kirsch said during a recent interview on EpochTV’s “American Thought Leaders” program.
He said the COVID protocols hospitals have followed, although sanctioned by the federal health agencies, added to the death toll.
“It’s approved by the NIH, and if [hospitals] stick with the NIH and the CDC approved protocols, [hospitals] get compensated, and there’s no liability,” said Kirsch.
Early Treatment Works
At the start of the pandemic, Kirsch donated a million dollars and raised five million to fund clinical trials and recruited a 14-person scientific advisory board all to test repurposed drugs for COVID treatment.
“What we discovered was that many of these drugs were remarkably effective,” said Kirsch. One of the repurposed drugs, fluvoxamine, was successful in treating COVID and featured on 60 Minutes, but was not mentioned that it was highly effective in treating COVID.
If patients started taking the drug right when they started to develop COVID symptoms, the results were very good with no hospitalizations. After the study, Kirsch tried to get emergency authorization from the FDA but was told that the study had insufficient evidence.
“This is something that is killing people, that is a world emergency, and it took the FDA six weeks to act on data that could be reviewed in an hour. The fix is in, they’re not going to approve anything,” said Kirsch.
Even after more studies came out proving that this drug was effective in curing COVID, the FDA still rejected its use but approved a bivalent COVID booster with no human trials.
“There’s no evidence of a benefit [for bivalent booster], yet they approve it for that, but for fluvoxamine, which had a stellar track record and an incredible safety record for 30 years. They said nope, insufficient evidence,” said Kirsch.
The Epoch Times reached out to the FDA for comment.
Because Kirsch had limited funds, he said he also went to the Bill and Melinda Gates Foundation to ask: “Hey, would you help me fund early treatment because that’s the fastest, safest, cheapest way? Let’s try what’s on the shelf. They said, ‘nope, we’re out of money.’”